Menu
Search
|

Menu

Close
X

Insmed Inc INSM.OQ (NASDAQ Stock Exchange Global Select Market)

17.27 USD
+0.43 (+2.55%)
As of Nov 16
chart
Previous Close 16.84
Open 16.73
Volume 295,439
3m Avg Volume 336,184
Today’s High 17.44
Today’s Low 16.43
52 Week High 33.94
52 Week Low 13.86
Shares Outstanding (mil) 77.09
Market Capitalization (mil) 1,232.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.10 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-3.029
FY17
-2.865
FY16
-2.848
FY15
-2.025
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
4.23
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
107.02
13.84
LT Debt to Equity (MRQ)
vs sector
107.02
9.93
Return on Investment (TTM)
vs sector
-55.12
13.58
Return on Equity (TTM)
vs sector
-83.65
15.11

EXECUTIVE LEADERSHIP

William Lewis
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $566,500.00
Bonus: --
Paolo Tombesi
Chief Financial Officer, Since 2017
Salary: $253,750.00
Bonus: $40,000.00
Roger Adsett
Chief Commercial Officer, Since 2016
Salary: $436,450.00
Bonus: --
Christine Pellizzari
Chief Legal Officer, Since 2018
Salary: $415,340.00
Bonus: --
Paul Streck
Chief Medical Officer, Since 2017
Salary: $244,920.00
Bonus: $40,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Finderne Ave Bldg 10
BRIDGEWATER   NJ   08807-3365

Phone: +1908.9779900

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

SPONSORED STORIES